Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

The increasing burden of costs associated with novel cancer therapies is becoming untenable. In Europe and Canada, assessment frameworks have been developed to attribute value to novel therapies and ultimately facilitate access to cancer drug funding. A review of the two frameworks has not previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Matthew C, Chan, Kelvin KW, Sabharwal, Mona, Fields, Anthony, Chambers, Alexandra, Evans, William K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703384/
https://www.ncbi.nlm.nih.gov/pubmed/29209520
http://dx.doi.org/10.1136/esmoopen-2016-000124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703384/
https://www.ncbi.nlm.nih.gov/pubmed/29209520
http://dx.doi.org/10.1136/esmoopen-2016-000124

Ejemplares similares